- Home
- CMBM vs OCUP Comparison
CMBM vs OCUP Comparison
Compare CMBM & OCUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBM
- OCUP
- Stock Information
- Founded
- CMBM 2011
- OCUP 2018
- Country
- CMBM United States
- OCUP United States
- Employees
- CMBM N/A
- OCUP N/A
- Industry
- CMBM Radio And Television Broadcasting And Communications Equipment
- OCUP Biotechnology: Pharmaceutical Preparations
- Sector
- CMBM Technology
- OCUP Health Care
- Exchange
- CMBM Nasdaq
- OCUP Nasdaq
- Market Cap
- CMBM 50.8M
- OCUP 53.1M
- IPO Year
- CMBM 2019
- OCUP N/A
- Fundamental
- Price
- CMBM $1.64
- OCUP $1.32
- Analyst Decision
- CMBM Buy
- OCUP Strong Buy
- Analyst Count
- CMBM 6
- OCUP 3
- Target Price
- CMBM $6.13
- OCUP $18.67
- AVG Volume (30 Days)
- CMBM 59.3K
- OCUP 86.6K
- Earning Date
- CMBM 10-31-2024
- OCUP 11-11-2024
- Dividend Yield
- CMBM N/A
- OCUP N/A
- EPS Growth
- CMBM N/A
- OCUP N/A
- EPS
- CMBM N/A
- OCUP N/A
- Revenue
- CMBM $171,535,000.00
- OCUP $16,449,000.00
- Revenue This Year
- CMBM N/A
- OCUP N/A
- Revenue Next Year
- CMBM $19.77
- OCUP $258.69
- P/E Ratio
- CMBM N/A
- OCUP N/A
- Revenue Growth
- CMBM N/A
- OCUP N/A
- 52 Week Low
- CMBM $1.52
- OCUP $1.15
- 52 Week High
- CMBM $6.50
- OCUP $3.53
- Technical
- Relative Strength Index (RSI)
- CMBM 41.19
- OCUP 48.70
- Support Level
- CMBM $1.71
- OCUP $1.25
- Resistance Level
- CMBM $1.84
- OCUP $1.35
- Average True Range (ATR)
- CMBM 0.13
- OCUP 0.08
- MACD
- CMBM -0.01
- OCUP 0.01
- Stochastic Oscillator
- CMBM 6.38
- OCUP 29.17
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About OCUP Ocuphire Pharma Inc.
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.